After a recent coronary event,* nonadherence could be getting in the way of your patients reaching and remaining at LDL-C target1-4
49% higher rate of cardiovascular events in patients who failed to reach LDL-C goal5†
The effect of LEQVIO® on cardiovascular morbidity and mortality has not been determined.
*An event is defined as acute coronary syndrome (unstable angina, STEMI, or NSTEMI) and/or coronary revascularization.6
†Based on study (n=38,110,734) data that evaluated the annual cardiovascular event rates in a subset of guideline-defined high-risk patients of the Family Heart Database, which comprises diagnostic, procedure, lab, and prescription data from claims in the US from 2012 to 2021.5
2025 ACC/AHA Joint Committee Clinical Practice Guideline for the Management of Patients with Acute Coronary Syndromes7
Latest clinical practice guideline recommends adding nonstatin LLT, including LEQVIO, as an option for LDL-C management after ACS in patients with elevated LDL-C despite statin therapy.
‡Class (STRENGTH) of Recommendation: COR 1/Class 1 (STRONG); COR 2a/Class 2a (MODERATE)
§Nonstatin lipid-lowering agents include ezetimibe, evolocumab, alirocumab, inclisiran, and bempedoic acid.
Reprinted from J Am Coll Cardiol., Kumbhani D, Cibotti-Sun, M, Moore, M. 2025 Acute Coronary Syndromes Guideline-at-a-Glance. JACC. null2025, 0 (0). https://doi.org/10.1016/j.jacc.2025.01.018, Copyright 2025, with permission from Elsevier.
Latest 2025 ACC/AHA Joint Committee Clinical Practice Guideline recommends more aggressive LDL-C targets for patients after a recent ACS.
The guideline recommends adding a nonstatin lipid-lowering therapy, including LEQVIO, for patients with ACS and LDL-C ≥70 mg/dL despite maximally-tolerated statin therapy. For patients with ACS and LDL-C 55 to <70 m/dL, adding a nonstatin, including LEQVIO, is considered reasonable.
Adherence Challenges
Many patients struggle to adhere to self-administered treatments
50%
of patients discontinue statins within 1 year1-4
>30%
of patients discontinue PCSK9 mAbs within 6 months8,9‖¶
¶In a retrospective cohort study of pharmacy and health plan claims of patients who initiated PCSK9 mAbs (N=13151) between January 1, 2016, and June 30, 2016, who were followed for a minimum of 6 months after their first prescription fill. Discontinuation was defined as the gap of 60 days or more between the last day of supply of one prescription and the start of the next prescription. Specific reasons for discontinuation were unknown; however, it could have been due to poor tolerability, noncompliance, unwillingness to perform injections, and insurance or cost issues. Gaps in therapy were derived from actual prescription fill data.8
Sample Patient Profile
After a recent coronary event,* patients need immediate action to reduce LDL-C10
Michael, Patient With Coronary Artery Disease (CAD)
Recent Event: NSTEMI <12 months ago
Recent Procedure: PCI
LDL-C Level: 105 mg/dL
Additional CV Risk Factors: Hyperlipidemia, type 2 diabetes, hypertension
Current LDL-C Treatment: High-intensity statin
When statins aren’t enough, look to LEQVIO
Learn how to start your patients on LEQVIO
Discover resources for your practice and your patients.
Ready to add LEQVIO?
LEQVIO Patient Brochure
Spanish LEQVIO Patient Brochure
Dive into real-world adherence
See the data for the 12-month real-world adherence study
